Research progress of lung cancer chemotherapy

Times of life "to fight cancer to enjoy life," the Forum a series of reports

Chemotherapy is one of the means of treatment of lung cancer, especially in the past 10 years, chemotherapy drugs and treatment programs to enhance the development of non-small cell lung cancer after chemotherapy efficacy, reduced toxicity.

In 1995, the British medical journal published by the international non-small cell lung cancer collaborative group of 52 global research summary, when the results of the view that non-small cell lung cancer adjuvant chemotherapy after surgery or not, patients with metastasis and recurrence rate and no difference in survival time .

Therefore, at the time to surgical resection of non-small cell lung cancer, are not in favor of chemotherapy after surgery.

Subsequent years, many new, more effective chemotherapy drugs are all listed, the more clinical trials are under way.

In 2003, the international adjuvant chemotherapy for lung cancer in the United States Conference of Clinical Oncology (ASCO) meeting on the report of 1867 cases of non-small cell lung cancer research findings: post-operative use of platinum drugs in patients with adjuvant chemotherapy and no chemotherapy, compared to patients , 5-year survival rates were 44% and 40%, which can prove that chemotherapy can improve the efficacy, but 23 percent of patients have a more obvious toxicity.

By 2004, the National Cancer Institute of Canada study, 482 cases of Ⅰ B and Ⅱ non-small cell lung cancer patients, vinorelbine plus cisplatin chemotherapy and non-chemotherapy compared to 5-year survival rates were 69% and 54 %, chemotherapy group of 5-year survival rate increased by 15%. That same year, the United States reported in 344 cases of patients, post-operative use of carboplatin in the treatment of Catalonia, the 4-year survival rate was 71 percent, than non-chemotherapy increased 12%.

Now, non-small cell lung cancer has begun to take shape a consensus, usually加泰索Dili cisplatin, paclitaxel, gemcitabine, vinorelbine, etc. A. According to patient's specific circumstances, to choose different combinations can be achieved to improve efficacy, reduce toxicity purpose, especially targeting drug emerged, its mechanism and different from traditional chemotherapy drugs. Traditional chemotherapy drugs are cytotoxic drugs, is toxic to kill tumor cells, but at the same time will inevitably harm normal cells. The targeted drugs into tumor cells can block the adoption of specific epidermal growth factor receptor pathway, inhibit tumor cell proliferation, invasion, metastasis, adverse reactions of light, the patient can be well tolerated.